vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Perella Weinberg Partners (PWP). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $219.2M, roughly 1.1× Perella Weinberg Partners). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 6.3%, a 4.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -2.9%). Perella Weinberg Partners produced more free cash flow last quarter ($30.5M vs $29.1M). Over the past eight quarters, Perella Weinberg Partners's revenue compounded faster (46.5% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.
ANIP vs PWP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $219.2M |
| Net Profit | $27.5M | $13.8M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 8.5% |
| Net Margin | 11.1% | 6.3% |
| Revenue YoY | 29.6% | -2.9% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $219.2M | ||
| Q3 25 | $227.8M | $164.6M | ||
| Q2 25 | $211.4M | $155.3M | ||
| Q1 25 | $197.1M | $211.8M | ||
| Q4 24 | $190.6M | $225.7M | ||
| Q3 24 | $148.3M | $278.2M | ||
| Q2 24 | $138.0M | $272.0M | ||
| Q1 24 | $137.4M | $102.1M |
| Q4 25 | $27.5M | $13.8M | ||
| Q3 25 | $26.6M | $6.0M | ||
| Q2 25 | $8.5M | $2.7M | ||
| Q1 25 | $15.7M | $17.3M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $16.4M | ||
| Q2 24 | $-2.3M | $-66.0M | ||
| Q1 24 | $18.2M | $-35.8M |
| Q4 25 | 14.1% | 8.5% | ||
| Q3 25 | 15.9% | 5.4% | ||
| Q2 25 | 6.6% | 5.8% | ||
| Q1 25 | 13.3% | 5.5% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -13.8% | 12.9% | ||
| Q2 24 | 3.7% | -30.2% | ||
| Q1 24 | 14.8% | -52.4% |
| Q4 25 | 11.1% | 6.3% | ||
| Q3 25 | 11.7% | 3.6% | ||
| Q2 25 | 4.0% | 1.8% | ||
| Q1 25 | 8.0% | 8.2% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 5.9% | ||
| Q2 24 | -1.7% | -24.3% | ||
| Q1 24 | 13.2% | -35.1% |
| Q4 25 | $1.14 | $0.11 | ||
| Q3 25 | $1.13 | $0.08 | ||
| Q2 25 | $0.36 | $0.04 | ||
| Q1 25 | $0.69 | $0.24 | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | $0.24 | ||
| Q2 24 | $-0.14 | $-1.21 | ||
| Q1 24 | $0.82 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $255.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $-127.4M |
| Total Assets | $1.4B | $797.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $255.9M | ||
| Q3 25 | $262.6M | $185.5M | ||
| Q2 25 | $217.8M | $145.0M | ||
| Q1 25 | $149.8M | $111.2M | ||
| Q4 24 | $144.9M | $407.4M | ||
| Q3 24 | $145.0M | $335.1M | ||
| Q2 24 | $240.1M | $185.3M | ||
| Q1 24 | $228.6M | $156.7M |
| Q4 25 | $540.7M | $-127.4M | ||
| Q3 25 | $505.8M | $-302.4M | ||
| Q2 25 | $436.8M | $-318.4M | ||
| Q1 25 | $418.6M | $-323.1M | ||
| Q4 24 | $403.7M | $-421.4M | ||
| Q3 24 | $405.9M | $-360.8M | ||
| Q2 24 | $455.8M | $-283.0M | ||
| Q1 24 | $452.0M | $161.9M |
| Q4 25 | $1.4B | $797.6M | ||
| Q3 25 | $1.4B | $650.2M | ||
| Q2 25 | $1.3B | $606.7M | ||
| Q1 25 | $1.3B | $570.5M | ||
| Q4 24 | $1.3B | $876.8M | ||
| Q3 24 | $1.3B | $810.9M | ||
| Q2 24 | $920.8M | $645.5M | ||
| Q1 24 | $914.5M | $583.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $34.8M |
| Free Cash FlowOCF − Capex | $29.1M | $30.5M |
| FCF MarginFCF / Revenue | 11.8% | 13.9% |
| Capex IntensityCapex / Revenue | 0.5% | 2.0% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.52× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-34.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $34.8M | ||
| Q3 25 | $44.1M | $59.2M | ||
| Q2 25 | $75.8M | $56.1M | ||
| Q1 25 | $35.0M | $-176.5M | ||
| Q4 24 | $15.9M | $223.4M | ||
| Q3 24 | $12.5M | $200.3M | ||
| Q2 24 | $17.4M | $90.0M | ||
| Q1 24 | $18.3M | $-206.3M |
| Q4 25 | $29.1M | $30.5M | ||
| Q3 25 | $38.0M | $57.6M | ||
| Q2 25 | $71.8M | $55.3M | ||
| Q1 25 | $32.5M | $-177.6M | ||
| Q4 24 | $13.5M | $207.0M | ||
| Q3 24 | $7.7M | $199.3M | ||
| Q2 24 | $13.0M | $83.7M | ||
| Q1 24 | $13.7M | $-214.8M |
| Q4 25 | 11.8% | 13.9% | ||
| Q3 25 | 16.7% | 35.0% | ||
| Q2 25 | 34.0% | 35.6% | ||
| Q1 25 | 16.5% | -83.8% | ||
| Q4 24 | 7.1% | 91.7% | ||
| Q3 24 | 5.2% | 71.6% | ||
| Q2 24 | 9.4% | 30.8% | ||
| Q1 24 | 10.0% | -210.3% |
| Q4 25 | 0.5% | 2.0% | ||
| Q3 25 | 2.7% | 0.9% | ||
| Q2 25 | 1.9% | 0.5% | ||
| Q1 25 | 1.3% | 0.5% | ||
| Q4 24 | 1.3% | 7.3% | ||
| Q3 24 | 3.2% | 0.4% | ||
| Q2 24 | 3.2% | 2.3% | ||
| Q1 24 | 3.3% | 8.3% |
| Q4 25 | 1.10× | 2.52× | ||
| Q3 25 | 1.66× | 9.85× | ||
| Q2 25 | 8.87× | 20.50× | ||
| Q1 25 | 2.23× | -10.18× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 12.23× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PWP
Segment breakdown not available.
